Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GSK3008348 in Healthy Volunteers and IPF Patients
NCT02612051Phase 1Completed
- Sponsor
- GSK
- Start
- Dec 2015
- Primary completion
- Jun 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GSK3008348 in idiopathic pulmonary fibrosis (IPF) (8 cohorts), sponsored by GSK. Primary endpoints: Number of participants with adverse events, Temperature and 13 more. Started Dec 2015; status: completed.
02
Drugs
GSK3008348
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on NCT02612051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02612051.